Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
Nivolumab (an anti –programmed death-1 antibody) is an adjuvant standard of care for patients with high-risk resected melanoma, although a watch-and-wait strategy remains an option. In the absence of head-to-head evidence, an indirect treatment comparison (ITC) of adjuvant nivolumab versus placebo, the proxy for a w atch-and-wait strategy, was conducted in patients with high-risk resected melanoma.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Jeffrey S. Weber, Paolo A. Ascierto, Mark R. Middleton, Delphine Hennicken, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati, Andriy Moshyk, Dirk Schadendorf Tags: Original Research Source Type: research